Navamedic Management
Management criteria checks 2/4
Navamedic's CEO is Kathrine E. Andreassen, appointed in Jan 2019, has a tenure of 5.92 years. total yearly compensation is NOK5.51M, comprised of 55.7% salary and 44.3% bonuses, including company stock and options. directly owns 4.37% of the company’s shares, worth NOK19.99M. The average tenure of the management team and the board of directors is 5.5 years and 2 years respectively.
Key information
Kathrine E. Andreassen
Chief executive officer
NOK 5.5m
Total compensation
| CEO salary percentage | 55.7% |
| CEO tenure | 5.9yrs |
| CEO ownership | 4.4% |
| Management average tenure | 5.5yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
Is Navamedic (OB:NAVA) Using Too Much Debt?
Sep 19
Here's Why Navamedic (OB:NAVA) Can Manage Its Debt Responsibly
Feb 18Shareholders Can Be Confident That Navamedic's (OB:NAVA) Earnings Are High Quality
Nov 09Is Navamedic (OB:NAVA) A Risky Investment?
Nov 02Here's Why Navamedic (OB:NAVA) Has A Meaningful Debt Burden
Feb 22We Think Navamedic (OB:NAVA) Can Stay On Top Of Its Debt
Sep 04Is Navamedic (OB:NAVA) Using Too Much Debt?
Apr 12If You Had Bought Navamedic (OB:NAVA) Stock Three Years Ago, You Could Pocket A 166% Gain Today
Feb 18
Is Navamedic (OB:NAVA) Using Debt Sensibly?
Dec 07CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NOK 20m |
| Jun 30 2024 | n/a | n/a | NOK 27m |
| Mar 31 2024 | n/a | n/a | -NOK 11m |
| Dec 31 2023 | NOK 6m | NOK 3m | NOK 3m |
| Sep 30 2023 | n/a | n/a | NOK 31m |
| Jun 30 2023 | n/a | n/a | NOK 23m |
| Mar 31 2023 | n/a | n/a | NOK 43m |
| Dec 31 2022 | NOK 5m | NOK 3m | NOK 29m |
| Sep 30 2022 | n/a | n/a | NOK 12m |
| Jun 30 2022 | n/a | n/a | NOK 8m |
| Mar 31 2022 | n/a | n/a | NOK 4m |
| Dec 31 2021 | NOK 5m | NOK 2m | NOK 618k |
| Sep 30 2021 | n/a | n/a | -NOK 7m |
| Jun 30 2021 | n/a | n/a | -NOK 6m |
| Mar 31 2021 | n/a | n/a | -NOK 8m |
| Dec 31 2020 | NOK 4m | NOK 2m | -NOK 16m |
| Sep 30 2020 | n/a | n/a | -NOK 22m |
| Jun 30 2020 | n/a | n/a | -NOK 24m |
| Mar 31 2020 | n/a | n/a | -NOK 26m |
| Dec 31 2019 | NOK 3m | NOK 2m | -NOK 16m |
Compensation vs Market: Kathrine E.'s total compensation ($USD486.28K) is above average for companies of similar size in the Norwegian market ($USD284.90K).
Compensation vs Earnings: Kathrine E.'s compensation has been consistent with company performance over the past year.
CEO
Kathrine E. Andreassen (58 yo)
5.9yrs
Tenure
NOK 5,509,000
Compensation
Ms. Kathrine E. Gamborg Andreassen serves as Director at Observe Medical Asa since June 13, 2019. Ms. Andreassen has been Chief Executive Officer of Navamedic ASA since January 1, 2019. She is Chairman of...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 5.9yrs | NOK 5.51m | 4.37% NOK 20.0m | |
| Chief Financial Officer | 5yrs | NOK 3.14m | 2.01% NOK 9.2m | |
| Chief Operating Officer | less than a year | no data | 0.44% NOK 2.0m | |
| Chief Scientific Officer | 5.9yrs | no data | 3.4% NOK 15.5m | |
| Chief Business Development Officer | no data | no data | 3.26% NOK 14.9m |
5.5yrs
Average Tenure
58yo
Average Age
Experienced Management: NAVA's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Director | less than a year | no data | 0.28% NOK 1.3m | |
| Independent Chair of the Board | 7.9yrs | NOK 235.00k | no data | |
| Director | less than a year | no data | no data | |
| Director | 1.5yrs | no data | no data | |
| Independent Director | 3.5yrs | NOK 210.00k | no data | |
| Independent Director | 2.5yrs | NOK 210.00k | no data |
2.0yrs
Average Tenure
65yo
Average Age
Experienced Board: NAVA's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Navamedic ASA is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Espen Jørgensen | DNB Markets |
| Gediminas Ruginis | Norne Securities AS |
| Juste Subataviciute | Norne Securities AS |